ZIM Laboratories Valuation

Is ZIMLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZIMLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ZIMLAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ZIMLAB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZIMLAB?

Key metric: As ZIMLAB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ZIMLAB. This is calculated by dividing ZIMLAB's market cap by their current earnings.
What is ZIMLAB's PE Ratio?
PE Ratio	33.3x
Earnings	₹161.50m
Market Cap	₹5.17b

ZIMLAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.6x
Enterprise Value/EBITDA	14.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does ZIMLAB's PE Ratio compare to its peers?

The above table shows the PE ratio for ZIMLAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	28x
524731 Jenburkt Pharmaceuticals	18.2x	n/a	₹5.4b
ACCENTMIC Accent Microcell	15.8x	n/a	₹5.1b
INFINIUM Infinium Pharmachem	47.8x	n/a	₹4.6b
524500 Kilitch Drugs (India)	30.1x	n/a	₹4.9b
ZIMLAB ZIM Laboratories	33.3x	n/a	₹5.2b

Price-To-Earnings vs Peers: ZIMLAB is expensive based on its Price-To-Earnings Ratio (33.3x) compared to the peer average (28x).

Price to Earnings Ratio vs Industry

How does ZIMLAB's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.5x	n/a	US$69.13m
524652 Ind-Swift	2x	n/a	US$12.99m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: ZIMLAB is good value based on its Price-To-Earnings Ratio (33.3x) compared to the Indian Pharmaceuticals industry average (34.2x).

Price to Earnings Ratio vs Fair Ratio

What is ZIMLAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZIMLAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	33.3x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ZIMLAB's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Sanofi India

₹143.0b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,196.05

0.8%

-22.8%

Colinz Laboratories

₹134.8m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹56.10

3.0%

37.2%